BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

...remdesivir (GS-5734) Viracept, nelfinavir (ARV-SR0121, AG-1343) Tybost, cobicistat (GS-9350, gs 9350) Human...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

...for COVID-19; Janssen and BARDA will screen a library of existing antivirals to treat COVID-19. Darunavir/cobicistat...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...was new evidence of added benefit over existing treatments based on long-term data. For Genvoya elvitegravir/cobicistat/emtricitabine/tenofovir...
...data from randomized controlled trials to ICER that showed that Genvoya was superior to Stribild elvitegravir/cobicistat/emtricitabine/tenofovir...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Co. Ltd. (Tokyo:4502) Enbrel etanercept $5,782.8 $3,925.2 $5,233.6 -9% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya elvitegravir/ cobicistat/emtricitabine/...
BioCentury | Jul 20, 2018
Clinical News

FDA approves J&J's Symtuza for HIV-1 infection in adults

...FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults...
...40 kg. The once-daily fixed-dose combination tablet comprises Prezista darunavir, a second-generation protease inhibitor; Tybost cobicistat...
...TMC114 (Compound #), darunavir (Generic), Prezista (Informal) Symtuza (Brand), Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Generic), Symtuza (Other) Tybost, cobicistat (GS-9350, gs 9350) Gilead...
BioCentury | May 1, 2018
Company News

HCV drug sales drag down Gilead's 1Q18 earnings

...sales figures of $3.2 billion (see BioCentury Extra, Feb. 6) . HIV drugs Genvoya treatment elvitegravir/cobicistat/emtricitabine/tenofovir...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Gilead Sciences Inc. (NASDAQ:GILD) Epclusa sofosbuvir/velpatasvir $1,752.0 $2,945.0 $3,926.7 124% Gilead Sciences Inc. (NASDAQ:GILD) Genvoya elvitegravir/cobicistat/emtricitabine/tenofovir...
...tenofovir $1,186.0 $834.0 $1,112.0 -6% Gilead Sciences Inc. (NASDAQ:GILD) / Japan Tobacco Inc. (Tokyo:2914) Stribild elvitegravir/cobicistat/emtricitabine/tenofovir...
BioCentury | Oct 27, 2017
Clinical News

EC approves Symtuza for HIV-1, Janssen submits NDA to FDA

...& Development LLC unit submitted an NDA to FDA for a once-daily fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir...
...body weight of ≥40 kg. The regimen comprises Prezista darunavir, a second-generation protease inhibitor; Tybost cobicistat...
...transcriptase inhibitor; and tenofovir alafenamide, a prodrug of the nucleotide analog reverse transcriptase inhibitor tenofovir. Tybost...
BioCentury | May 5, 2017
Clinical News

ABX464 reduces HIV reservoirs in Ph IIa trial

...their current antiretroviral therapy (ART) consisting of Prezista darunavir plus ritonavir or Prezista pus Tybost cobicistat...
BioCentury | Feb 3, 2017
Clinical News

Stribild regulatory update

...FDA approved an sNDA from Gilead for Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate to treat HIV-1 infection in...
...resistance to Stribild’s components. Stribild is a once-daily tablet comprising Vitekta elvitegravir and Gilead’s Tybost cobicistat...
...City, Calif. Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Product: Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate Business: Infectious Julian Zhu elvitegravir/cobicistat/emtricitabine/tenofovir...
Items per page:
1 - 10 of 193